The British non-profit organization Cystic Fibrosis Trust has launched a survey entitled “Cystic Fibrosis & Treatment – What Matters to You?” for patients to share their thoughts and needs regarding treatment for cystic fibrosis (CF). With the motto “Use your voice to support access to transformational treatments,”…
News
Galapagos NV, a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action for treating diseases such as cystic fibrosis as well as inflammation and other indications, recently announced that its drug candidate GLPG2665 has been chosen to be developed as a next-generation…
Researchers from the University of Queensland (UQ), Australia, have recently released findings from their scientific literature review in an effort to identify all cases of Burkholderia pseudomallei infections in cystic fibrosis (CF) patients globally, the potential risk factors for acquisition, clinical consequences, and optimal treatment strategies. The findings entitled, “An international,…
Exciting new research, partly funded by the U.K. Cystic Fibrosis Trust and the Robert Luff Foundation and announced at the Trust’s U.K. CF Conference last week, shows promising results in reconditioning poorly functioning donor lungs and reducing acute organ rejection in a trial on pigs, the Trust reports. A…
Vertex Pharmaceuticals Incorporated is a global biotechnology company whose corporate mission is to discover, develop and commercialize innovative medicines that can help people with serious diseases lead better lives. Vertex initiated its CF research program in 1998 as part of a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT),…
Proteostasis Therapeutics, Inc. (PTI), a company that develops disease-modifying therapeutics for diseases involving protein processing, recently announced at a presentation during the 29th Annual North American Cystic Fibrosis Conference data on its transmembrane conductance regulator (CFTR) amplifier program for use in combined treatments for patients with cystic fibrosis (CF). In…
Alcresta, a company dedicated to developing and commercializing novel enzyme-based products that address the challenges faced by patients with gastrointestinal disorders and rare diseases such as cystic fibrosis recently presented at the 29th Annual North American Cystic Fibrosis Conference (NACFC) new clinical results reporting on its product and technology. The conference is taking…
Celtaxsys, a pharmaceutical company focused on novel therapeutics to treat inflammatory diseases, announced that it is beginning enrollment of patients for a phase 2 clinical trial to test the efficacy of acebilustat in patients with cystic fibrosis (CF). The study will be conducted in the United States and European Union…
Concert Pharmaceuticals will present data from a Phase 1 single ascending dose trial of experimental CF therapy CTP-656, a next generation potentiator developed for the treatment of cystic fibrosis during the 29th Annual North American Cystic Fibrosis Conference this week in Phoenix, Arizona. The study being presented is entitled ”…
This week, Vertex Pharmaceuticals Incorporated, a global biotechnology company that aims to discover, develop and commercialize innovative new medicines for diseases such as cystic fibrosis, announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for the use of…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.